NCT04861948

IBI188 Combination Therapy in Solid Tumors

Phase Ib Study to Evaluate the Efficacy, Safety and Tolerability of IBI188 Combination Therapy in Subjects With Advanced Malignancies

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

A Phase Ib study aim to evaluate the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies

Conditions

• Solid Tumors
• Lung Adenocarcinoma
• Osteosarcoma

Interventions

Type	Name	Description
DRUG	IBI188	intravenous
DRUG	GM-CSF	subcutaneous injection
DRUG	Cisplatin/Carboplatin	intravenous
DRUG	Bevacizumab	intravenous
DRUG	Sintilimab	intravenous
DRUG	Pemetrexed	intravenous

Timeline

• Start date: 2021-05-25
• Primary completion: 2022-07-30
• Completion: 2022-07-30
• First posted: 2021-04-27
• Last updated: 2022-10-04

Locations

1 site across 1 country: China